Noxiptiline: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 21: | Line 21: | ||
{{stub}} | {{stub}} | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
<gallery> | |||
File:Noxiptilin.png|Noxiptiline | |||
File:Noxiptilin-3D-spacefill.png|Noxiptiline 3D Spacefill Model | |||
File:Noxiptiline_synthesis.svg|Noxiptiline Synthesis | |||
</gallery> | |||
Latest revision as of 01:38, 18 February 2025
Noxiptiline (also known as Agedal, Elronon, Nogedal, Tolnodin, Tolnox) is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1970s for the treatment of depression. It is a strong norepinephrine reuptake inhibitor with only weak effects on serotonin and dopamine reuptake.
Pharmacology[edit]
Noxiptiline acts as a norepinephrine reuptake inhibitor and to a lesser extent as a serotonin reuptake inhibitor. It has negligible effects on dopamine reuptake. Noxiptiline is a relatively strong antihistamine, which may contribute to its sedative properties. It also has anticholinergic effects.
Chemistry[edit]
Noxiptiline is a tricyclic compound, specifically a dibenzocycloheptene, and possesses three rings fused together with a side chain attached at one of the central ring atoms. This is the same three-ring core that is present in the antidepressant drugs amitriptyline and clomipramine, which are also TCAs.
Side effects[edit]
Common side effects of noxiptiline include dry mouth, blurred vision, dizziness, weight gain, urinary retention, constipation, and tachycardia (fast heart rate). More serious side effects may include suicidal ideation, mania, orthostatic hypotension, and cardiac arrhythmia.



